Tasigna and Retinal haemorrhage - a phase IV clinical study of FDA data

Summary:

Retinal haemorrhage is reported as a side effect among people who take Tasigna (nilotinib hydrochloride monohydrate), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Bisoprolol Fumarate, and have Carotid arteriosclerosis.

The phase IV clinical study analyzes which people have Retinal haemorrhage when taking Tasigna. It is created by eHealthMe based on reports of 31,413 people who have side effects when taking Tasigna from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Retinal haemorrhage?

Retinal haemorrhage (bleeding from retina) is found to be associated with 647 drugs and 783 conditions by eHealthMe. Check the latest studies of Retinal haemorrhage.

On Jul, 16, 2026

31,413 people reported to have side effects when taking Tasigna.
Among them, 12 people (0.04%) have Retinal haemorrhage.

Could Tasigna cause Retinal haemorrhage?

Among these 12 people:

How long have people been on Tasigna when they have Retinal haemorrhage? *

What is the gender of people who have Retinal haemorrhage when taking Tasigna? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Retinal haemorrhage when taking Tasigna? *

What are other drugs people take besides Tasigna? *

Bisoprolol Fumarate: 1 person, 8.33%

What are other side effects people have besides Retinal haemorrhage? *

Blindness Unilateral: 2 people, 16.67%
Retinal Tear: 2 people, 16.67%
Fatigue (feeling of tiredness): 2 people, 16.67%
Headache (pain in head): 2 people, 16.67%
Meningioma (a diverse set of tumours arising from the meninges): 1 person, 8.33%
Chest Pain: 1 person, 8.33%
Coronary Artery Stenosis (narrowing of coronary artery): 1 person, 8.33%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 8.33%
Diplopia (double vision): 1 person, 8.33%
Drowsiness: 1 person, 8.33%

What are the existing conditions these people have? *

Carotid Arteriosclerosis (plaque deposition in artery): 3 people, 25.00%
High Blood Pressure: 2 people, 16.67%
Myopathy (a muscular disease in which the muscle fibres do not function): 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Tasigna and have Retinal haemorrhage?

- Check whether Retinal haemorrhage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tasigna:

Tasigna (31,535 reports)

Retinal haemorrhage treatments and more:

Retinal haemorrhage (9,758 reports)

How severe was Retinal haemorrhage and when was it recovered:

Retinal haemorrhage in Tasigna

Expand to all the drugs that have ingredients of nilotinib hydrochloride monohydrate:

Retinal haemorrhage and drugs with ingredients of nilotinib hydrochloride monohydrate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tasigna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retinal haemorrhage:

Retinal haemorrhage (647 drugs)

Browse all the conditions that are associated with Retinal haemorrhage:

Retinal haemorrhage (783 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nilotinib hydrochloride monohydrate (the active ingredients of Tasigna) and Tasigna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.